Assessing TCR identity, knock-in efficiency, and potency for individualized TCR-T cell therapy.

Camperi, Julien; Devarajan, Srinidhi; McKay, Andrew; Tarighat, Somayeh; Chen, Dayue; Hu, Zhilan

Camperi, Julien; Devarajan, Srinidhi; McKay, Andrew; Tarighat, Somayeh; Chen, Dayue; Hu, Zhilan.

Afiliação

Camperi J; Cell Therapy Engineering and Development, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address: camperij@gene.com.
Devarajan S; Cell Therapy Engineering and Development, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
McKay A; Molecular Oncology, Genentech, 1 DNA Way, South San Francisco, CA 04080, USA.
Tarighat S; Cell Therapy Engineering and Development, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
Chen D; Cell Therapy Engineering and Development, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
Hu Z; Cell Therapy Engineering and Development, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address: zhl@gene.com.

J Immunol Methods ; 517: 113491, 2023 06.

Article em En | MEDLINE | ID: mdl-37187316

Assuntos

Antígenos de Neoplasias; Neoplasias; Humanos; Receptores de Antígenos de Linfócitos T; Linfócitos T; Neoplasias/terapia; Terapia Baseada em Transplante de Células e Tecidos

Palavras-chave

Cancer immunotherapy; Drug product; Individualized TCR-T therapy; Knock-in efficiency; Multiplex assays; Potency assay; TCR identity

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígenos de Neoplasias / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google